- Home
- REFI vs RCEL Comparison
REFI vs RCEL Comparison
Compare REFI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- RCEL
- Stock Information
- Founded
- REFI 2021
- RCEL N/A
- Country
- REFI United States
- RCEL United States
- Employees
- REFI N/A
- RCEL N/A
- Industry
- REFI Real Estate Investment Trusts
- RCEL Medical/Dental Instruments
- Sector
- REFI Real Estate
- RCEL Health Care
- Exchange
- REFI Nasdaq
- RCEL Nasdaq
- Market Cap
- REFI 274.3M
- RCEL 113.7M
- IPO Year
- REFI 2021
- RCEL N/A
- Fundamental
- Price
- REFI $13.48
- RCEL $6.23
- Analyst Decision
- REFI Strong Buy
- RCEL Strong Buy
- Analyst Count
- REFI 3
- RCEL 4
- Target Price
- REFI $20.00
- RCEL $13.75
- AVG Volume (30 Days)
- REFI 130.8K
- RCEL 1.2M
- Earning Date
- REFI 11-06-2025
- RCEL 11-06-2025
- Dividend Yield
- REFI 15.44%
- RCEL N/A
- EPS Growth
- REFI N/A
- RCEL N/A
- EPS
- REFI 1.84
- RCEL N/A
- Revenue
- REFI $56,608,781.00
- RCEL $74,884,000.00
- Revenue This Year
- REFI $9.93
- RCEL $22.92
- Revenue Next Year
- REFI $4.99
- RCEL $37.07
- P/E Ratio
- REFI $7.26
- RCEL N/A
- Revenue Growth
- REFI 2.58
- RCEL 38.32
- 52 Week Low
- REFI $12.76
- RCEL $3.60
- 52 Week High
- REFI $16.29
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- REFI 42.31
- RCEL 66.00
- Support Level
- REFI $13.08
- RCEL $4.12
- Resistance Level
- REFI $14.57
- RCEL $7.12
- Average True Range (ATR)
- REFI 0.32
- RCEL 0.35
- MACD
- REFI -0.11
- RCEL 0.24
- Stochastic Oscillator
- REFI 26.17
- RCEL 69.69
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.